LONNE Stock Overview
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF528.00 |
| 52 Week High | CHF599.80 |
| 52 Week Low | CHF309.60 |
| Beta | 0.64 |
| 1 Month Change | -2.08% |
| 3 Month Change | 18.36% |
| 1 Year Change | -8.17% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| LONNE | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0.9% | 2.0% | 3.0% |
| 1Y | -8.2% | -7.5% | -2.4% |
Return vs Industry: LONNE matched the Swiss Life Sciences industry which returned -7.5% over the past year.
Return vs Market: LONNE underperformed the Swiss Market which returned -2.4% over the past year.
Price Volatility
| LONNE volatility | |
|---|---|
| LONNE Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: LONNE has not had significant price volatility in the past 3 months.
Volatility Over Time: LONNE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 18,000 | Albert Baehny | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LONNE fundamental statistics | |
|---|---|
| Market cap | CHF37.95b |
| Earnings (TTM) | CHF654.00m |
| Revenue (TTM) | CHF6.72b |
58.0x
P/E Ratio5.6x
P/S RatioIs LONNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONNE income statement (TTM) | |
|---|---|
| Revenue | CHF6.72b |
| Cost of Revenue | CHF4.31b |
| Gross Profit | CHF2.40b |
| Other Expenses | CHF1.75b |
| Earnings | CHF654.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 9.07 |
| Gross Margin | 35.77% |
| Net Profit Margin | 9.74% |
| Debt/Equity Ratio | 29.4% |
How did LONNE perform over the long term?
See historical performance and comparison